Loading
Instead of blocking BTK, this pill destroys it, so it works even when the enzyme has mutated to escape every inhibitor.
Chimeric degradation-activating compound recruiting an E3 ligase to BTK. CaDAnCe-101 (phase 1, relapsed CLL/SLL after covalent BTKi, many with BTK mutations): ORR 86% in 66 patients with a manageable profile (fatigue, bruising, diarrhoea, neutropenia), updated at EHA 2026. Phase 3 CaDAnCe-304 (~500 patients) compares BGB-16673 with pirtobrutinib after covalent BTKi. The first BTK degrader in phase 3.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Heterobifunctional degrader: one end binds BTK (wild-type or C481/T474/L528 mutant), the other recruits an E3 ligase, tagging BTK for proteasomal destruction. Connects to BTK (Bruton tyrosine kinase).
1.BGB-16673 bridges BTK and an E3 ubiquitin ligase
Compare all products across the US, EU, UK, Japan, China and Australia →
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Fatigue | 25% | - |
| Contusion/bruising | 25% | - |
| Neutropenia | 25% | - |
≥25% in CaDAnCe-101. Rates read from the source. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BGB-16673" OR ABSTRACT:"BGB-16673") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BGB-16673, not a curated reading list.
Shares CaDAnCe-304, BTK (Bruton tyrosine kinase), Acquired resistance to every therapy, Mantle cell lymphoma.
Shares BTK (Bruton tyrosine kinase), Acquired resistance to every therapy, Chronic lymphocytic leukaemia.
Shares BTK (Bruton tyrosine kinase), BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia.
Shares BTK (Bruton tyrosine kinase), BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia.
Shares BTK (Bruton tyrosine kinase), Mantle cell lymphoma, Chronic lymphocytic leukaemia.
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
Shares BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia.
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.